Viewing Study NCT04224493

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:10 AM
Ignite Modification Date: 2026-01-06 @ 12:22 PM
Study NCT ID: NCT04224493
Status: RECRUITING
Last Update Posted: 2025-12-16
First Post: 2019-12-12
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Sponsor: Epizyme, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsed/Refractory Follicular Lymphoma View
None Follicular Lymphoma View
None Refractory Follicular Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Epizyme View
None Tazverik View
None Tazemetostat (EPZ-6438) View
None Lenalidomide View
None Revlimid View
None Rituximab View
None Rituxan View
None Follicular lymphoma View
None EZH2 View